Pre-made Mavrilimumab benchmark antibody ( Whole mAb, anti-CSF2RA therapeutic antibody, Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-339-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Mavrilimumab biosimilar, Whole mAb, Anti-CSF2RA Antibody: Anti-GMR/CD116/CSF2R/SMDP4/CDw116GMR-alpha/GMCSFR-alpha/GM-CSF-R-alpha therapeutic antibody
INN Name	Mavrilimumab
Target	CSF2RA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune
Conditions Approved	na
Conditions Active	Giant cell arteritis;COVID-19;Inflammation
Conditions Discontinued	Rheumatoid arthritis
Development Tech	CAT Phage Display